Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response

Journal of General Virology

Volumn 83, Issue 11, 2002, Pages 2723-2732

  Jeffs, S A ^a   Shotton, C ^a   Balfe, P ^a   McKeating, J A ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; MONOCLONAL ANTIBODY; POLYCLONAL ANTISERUM; PROTEIN PR12; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; BINDING COMPETITION; CHIMERA; CLADISTICS; CONTROLLED STUDY; EMBRYO; GENETIC CONSERVATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MODIFICATION; RAT; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0036842961     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-83-11-2723     Document Type: Article

References (39)

1. Albert, J., Abrahamsson, B., Nagy, K., Aurelius, E., Gaines, H., Nystrom, G. & Fenyo, E.-M. (1990). Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4, 107-112.
2. Albert, J., Bjorling, E., Vongegerfelt, A., Scarlatti, G., Zhang, Y. J., Fenyo, E-M. & Thorstensson, R. (1993). Antigen-detection is a reliable method for evaluating HIV/SIV neutralization assays. AIDS Research and Human Retroviruses 9, 501-504.
3. Baba, T. W., Liska, V., Hofmann-Lehmann, R., Vlasak, J., Xu, W., Ayehunie, S., Cavacini, L. A., Posner, M. R., Katinger, H., Stiegler, G., Bernacky, B. J., Rizvi, T. A., Schmidt, R., Hill, L. R., Keeling, M. E., Lu, Y., Wright, J. E., Chou, T.-C. & Ruprecht, R. M. (2000). Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus interaction. Nature Medicine 6, 200-206.
4. Back, N. K. T., Smith, L. & Dejog, J. J. (1994). An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199, 431-443.
5. Berman, P. W., Matthews, T. J., Riddle, L., Champe, M., Hobbs, M. R., Nakamura, G. R., Mercer, J. & Eastman, D. J. (1992). Antisera raised against gp120 from the MN isolate of HIV-1. Journal of Virology 66, 4464-4469.
6. Binley, J. M., Sanders, R. W., Las, B., Schuelke, N., Master, A., Guo, Y., Fajumo, F., Anselma, D. J., Maddon, P. J., Olson, W. C. & Moore, J. P. (2000). A recombinant human immunodeficiency virus type I envelope glycoprotein complex stabilised by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. Journal of Virology 74, 627-643.
7. Buchacher, A., Predl, R., Strutzenberger, K., Steinfellner, W., Trkola, A., Purtscher, M., Gruber, G., Tauer, C., Steindl, F., Jungbauer, A. & Katinger, H. (1994). Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Research and Human Retroviruses 10, 359-369.
8. Burton, D. R. & Montefiori, D. C. (1997). The antibody response in HIV-1 infection. AIDS 11, Supplement A, S87-S98.
9. Burton, D. R. & Moore, J. P. (1998). Why do we not have an HIV vaccine and how can we make one? Nature Medicine 4, 495-498.
10. Chackerian, B., Rudensey, L. M. & Overbaugh, J. (1997). Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus that evolve in the host alter recognition by neutralizing antibodies. Journal of Virology 71, 7719-7727.
11. Chakrabarti, B. K., Kong, W.-P., Wu, B.-Y., Yang, Z.-Y., Friborg, J., Ling, X., King, S. R., Montefiori, D. C. & Nable, G. J. (2002). Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. Journal of Virology 76, 5357-5368.
12. Connor, R.I., Korber, B. T. M., Graham, B. S., Hahn, B. H., Ho, D. D., Walker, B. D., Neuman, A. U., Vermund, S. H., Mestecky, J., Jackson, S., Fenamore, E., Cao, Y., Gao, F., Kalams, S., Kuntsman, K. J., McDonald, D., McWilliams, N., Trkola, A., Moore, J. P. & Wolinksky, S. M. (1998). Immunological and virological analyses of persons infected by human immunodeficiency virus type I while participating in trials of recombinant gp120 subunit vaccines. Journal of Virology 72, 1552-1576.
13. Cordell, J., Moore, J. P., Dean, C. J., Klasse, P. J., Weiss, R. A. & McKeating, J. A. (1991). Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro. Virology 185, 72-79.
14. Fenouillet, E., Blanes, N., Benjouad, A. & Gluckman, J. C. (1995). Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralizing activity. Clinical and Experimental Immunology 99, 419-424.
15. Jeffs, S. A., McKeating, J., Lewis, S., Craft, H., Biram, D., Stephens, P. E. & Brady, R. L. (1996). Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein. Journal of General Virology 77, 1403-1410.
16. IIIB gp120. Immunology Letters 79, 209-213.
17. LaCasse, R. A., Follis, K. E., Trahey, M., Scarborough, J. D., Littman, D. R. & Nunberg, J. H. (1999). Fusion-competent vaccines: broad neutralisation of primary isolates of HIV. Science 283, 357-362.
18. Lewis, J., Balfe, P., Arnold, C., Kaye, S., Tedder, R. S. & McKeating, J. M. (1998). Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. Journal of Virology 72, 8943-8951.
19. McKeating, J. A., Cordell, J., Dean, C. J. & Balfe P. (1992). Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type 1 gp120. Virology 191, 732-742.
20. McKeating, J. A., Shotton, C., Cordell, J., Graham, S., Balfe, P., Sullivan, N., Charles, M., Page, M., Bolmstedt, A., Olofsson, S., Wu, Z., Pinter, A., Dean, C., Sodroski, J. & Weiss, R. A. (1993). Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. Journal of Virology 67, 4932-4944.
21. McKeating, J. A., Shotton, C., Jeffs, S., Palmer, C., Hammond, A., Lewis, J., Oliver, K., May, J & Balfe, P. (1996). Immunogenicity of full-length and truncated forms of the human immunodeficiency virus type I envelope glycoprotein. Immunology Letters 51, 101-105.
22. Mascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, D., Louder, M. L., Brown, C. R., Sapan, C. V., Frankel., S. S., Lu, Y., Robb, M. L., Katinger, H. & Birx, D. L. (1999). Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. Journal of Virology 73, 4009-4018.
23. Mascola, J. R., Stiegler, G, VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S., Birx, D. L. & Lewis, M. G. (2000). Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Medicine 6, 207-210.
24. Montefiori, D. C. & Evans, T. G. (1999). Towards an HIV type1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Research and Human Retroviruses 15, 689-698.
25. Moore, J. P., Sattentau, Q., Wyatt, R. & Sodroski, J. (1994). Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. Journal of Virology 68, 469-484.
26. Moore, J. P., Trkola, A., Korber, B., Boots, L. J., Kessler, J., McCutchan, F. E., Mascola, J., Ho, D. D., Robinson, J. & Conley, A. J. (1995). A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. Journal of Virology 69, 122-30.
27. Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Ruker, F. & Katinger, H. (1993). A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. Journal of Virology 67, 6642-6647.
28. Nunberg, J. (2002). Retraction (letter). Science 296, 1025.
29. Nyambi, P. N., Gorny, M. K., Bastiani, L., Van Der Groen, G., Williams, C. & Zolla-Pazner, S. (1998). Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. Journal of Virology 72, 9384-9391.
30. Pollard, S. R., Rosa, M. D., Rosa, J. J. & Wiley, D. C. (1992). Truncated variants of gp120 bind CD4 with high affinity and suggest a minimum CD4 binding region. EMBO Journal 11, 585-591.
31. Reitter, J. N., Means, R. E. & Desrosiers, R. C. (1998). A role for carbohydrates in immune evasion in AIDS. Nature Medicine 4, 679-684.
32. Roben, P., Moore, J. P., Thali, M., Sodroski, J. & Barbas, C. F., III (1994). Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. Journal of Virology 68, 4821-4828.
33. Scarlatti, G. E., Albert, J., Rossi, P., Hodara, V., Biraghi, P., Muggiasca, L. & Fenyo, E.-M. (1993). Mother-to-child transmission of human immunodeficiency virus type 1 - correlation with neutralising antibodies against primary isolates. Journal of Infectious Diseases 168, 207-210.
34. Shotton, C., Arnold, C., Sattentau, Q., Sodroski, J. & McKeating, J. M. (1995). Identification and characterisation of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the HIV-1 envelope glycoprotein. Journal of Virology 69, 222-230.
35. Srivastava, I. K., Stamatatos, L., Legg, H., Kan, E., Fong, A., Coates, S. R., Leung, L., Wininger, M., Donnolly, J. L., Ulmer, J. B. & Barnett, S. W. (2002). Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. Journal of Virology 76, 2835-2847.
36. Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan, N., Srinivasan, K., Sodroski, J., Moore, J. P. & Katinger, H. (1996). Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. Journal of Virology 70, 1100-1108.
37. Von Gegerfelt, A., Albert, J., Morfeldt-Manson, L., Broliden, K. & Fenyo, E.-M. (1991). Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. Virology 185, 162-168.
38. Wyatt, R., Sullivan, N., Thali, M., Repke, H., Ho, D., Robinson, J., Posner, M. & Sodroski, J. (1993). Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. Journal of Virology 67, 4557-4565.
39. Yang, X., Florin, L., Farzan, M., Kolchinsky, P., Kwong, P. D., Sodroski, J. & Wyatt, R. (2000). Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. Journal of Virology 74, 4746-4754.